Clinical Trial Update: A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating HBV-specific antigen peptide- and HepG2 lysate-activated dendritic cells combined with transarterial chemoembolization in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• HBV-specific antigen peptide- and HepG2 lysate-activated dendritic cells
• Transarterial chemoembolization (TACE)

Snippet

Sponsor: Yuehua Huang | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED